251 related articles for article (PubMed ID: 34181866)
21. Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children.
Krishnan U; Takatsuki S; Ivy DD; Kerstein J; Calderbank M; Coleman E; Rosenzweig EB
Am J Cardiol; 2012 Dec; 110(11):1704-9. PubMed ID: 22917554
[TBL] [Abstract][Full Text] [Related]
22. Intravenous prostanoids in systemic sclerosis-associated pulmonary arterial hypertension: a single-centre experience.
Vlachou M; Fayed H; Dawson A; Reddecliffe S; Stevenson A; Thomson RJ; Schreiber BE; Coghlan JG
Rheumatology (Oxford); 2022 Mar; 61(3):1106-1114. PubMed ID: 34142120
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Value of Echocardiographic Variables Prior to and Following Initiation of Parenteral Prostacyclin Therapy: An Observational Study.
Shah T; Manthena P; Patel C; Chuah A; Hardin EA; Torres F; Bartolome SD; Chin KM
Chest; 2022 Sep; 162(3):669-683. PubMed ID: 35460641
[TBL] [Abstract][Full Text] [Related]
24. Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes.
Zheng Y; Yang T; Chen G; Hu E; Gu Q; Xiong C
Eur J Clin Pharmacol; 2014 Jan; 70(1):13-21. PubMed ID: 24026627
[TBL] [Abstract][Full Text] [Related]
25. Prostanoids for pulmonary arterial hypertension.
Galiè N; Manes A; Branzi A
Am J Respir Med; 2003; 2(2):123-37. PubMed ID: 14720012
[TBL] [Abstract][Full Text] [Related]
26. Prostanoid therapy for pulmonary arterial hypertension.
Strauss WL; Edelman JD
Clin Chest Med; 2007 Mar; 28(1):127-42; ix. PubMed ID: 17338932
[TBL] [Abstract][Full Text] [Related]
27. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
D'Alto M; Badagliacca R; Argiento P; Romeo E; Farro A; Papa S; Sarubbi B; Russo MG; Vizza CD; Golino P; Naeije R
Chest; 2020 Feb; 157(2):376-383. PubMed ID: 31563498
[TBL] [Abstract][Full Text] [Related]
28. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension.
Ivy DD; Doran AK; Smith KJ; Mallory GB; Beghetti M; Barst RJ; Brady D; Law Y; Parker D; Claussen L; Abman SH
J Am Coll Cardiol; 2008 Jan; 51(2):161-9. PubMed ID: 18191742
[TBL] [Abstract][Full Text] [Related]
29. [Characteristics of patients with connective tissue disease-associated pulmonary arterial hypertension treated with prostanoids: A multicenter retrospective study].
Genin V; Horeau-Langlard D; Diot E; Gagnadoux F; Lavigne C; Fournet M; Durant C; Agard C
Rev Med Interne; 2021 Dec; 42(12):825-831. PubMed ID: 34462153
[TBL] [Abstract][Full Text] [Related]
30. Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension.
Boucly A; Savale L; Jaïs X; Bauer F; Bergot E; Bertoletti L; Beurnier A; Bourdin A; Bouvaist H; Bulifon S; Chabanne C; Chaouat A; Cottin V; Dauphin C; Degano B; De Groote P; Favrolt N; Feng Y; Horeau-Langlard D; Jevnikar M; Jutant EM; Liang Z; Magro P; Mauran P; Moceri P; Mornex JF; Palat S; Parent F; Picard F; Pichon J; Poubeau P; Prévot G; Renard S; Reynaud-Gaubert M; Riou M; Roblot P; Sanchez O; Seferian A; Tromeur C; Weatherald J; Simonneau G; Montani D; Humbert M; Sitbon O
Am J Respir Crit Care Med; 2021 Oct; 204(7):842-854. PubMed ID: 34185620
[No Abstract] [Full Text] [Related]
31. Transition from parenteral to oral treprostinil in pulmonary arterial hypertension.
Chakinala MM; Feldman JP; Rischard F; Mathier M; Broderick M; Leedom N; Laliberte K; White RJ
J Heart Lung Transplant; 2017 Feb; 36(2):193-201. PubMed ID: 27469018
[TBL] [Abstract][Full Text] [Related]
32. Clinical value of prostacyclin and its analogs in the management of pulmonary arterial hypertension.
Dandel M; Hetzer R
Curr Vasc Pharmacol; 2003 Jun; 1(2):171-81. PubMed ID: 15320842
[TBL] [Abstract][Full Text] [Related]
33. Transitioning intravenous epoprostenol to oral selexipag in idiopathic pulmonary arterial hypertension: a case report.
Alexandre A; Furtado I; Carvalho L; Gonçalves F; Melo A; Alves J; Santos M; Reis A
ESC Heart Fail; 2023 Aug; 10(4):2722-2727. PubMed ID: 37336527
[TBL] [Abstract][Full Text] [Related]
34. Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.
Parikh KS; Doerfler S; Shelburne N; Kennedy K; Whitson J; Dahhan T; Fortin T; Rajagopal S
J Cardiovasc Pharmacol; 2020 Apr; 75(4):299-304. PubMed ID: 31934912
[TBL] [Abstract][Full Text] [Related]
35. Impact of Parenteral Prostanoids in Pulmonary Arterial Hypertension: The Relevance of Timing.
Papa S; Scoccia G; Serino G; Adamo FI; Jabbour JP; Caputo A; Boromei M; Filomena D; Laviola D; Maggio E; Manzi G; Mihai A; Recchioni T; Sabusco A; Valeri L; Vinciullo S; Vizza CD; Badagliacca R
J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959305
[TBL] [Abstract][Full Text] [Related]
36. Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies.
Zijlstra WMH; Douwes JM; Rosenzweig EB; Schokker S; Krishnan U; Roofthooft MTR; Miller-Reed K; Hillege HL; Ivy DD; Berger RMF
J Am Coll Cardiol; 2014 May; 63(20):2159-2169. PubMed ID: 24681143
[TBL] [Abstract][Full Text] [Related]
37. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
[TBL] [Abstract][Full Text] [Related]
39. Strategies for optimizing intravenous prostacyclin-analog therapy in patients with pulmonary arterial hypertension.
Ewert R; Habedank D; Halank M; Stubbe B; Opitz CF
Expert Rev Respir Med; 2022 Jan; 16(1):57-66. PubMed ID: 34846985
[TBL] [Abstract][Full Text] [Related]
40. Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY®.
Kitterman N; Poms A; Miller DP; Lombardi S; Farber HW; Barst RJ
Mayo Clin Proc; 2012 Sep; 87(9):825-34. PubMed ID: 22883740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
